# Tesamorelin Visceral Fat: What the Research Shows > Tesamorelin visceral fat research: VAT down 15.2% at 26 weeks, sustained ~18% at 52 weeks, a JAMA -42 cm2 effect and a 2026 meta-analysis -27.71 cm2. Findings in HIV-lipodystrophy cohorts. The most-studied tesamorelin endpoint, read trial by trial — the numbers, the durability, and the scope. ## In plain English This page reads the tesamorelin visceral fat record — visceral fat being the deep belly fat packed around the organs, the more harmful kind. In trials of people with HIV-associated fat redistribution, tesamorelin selectively shrank this deep fat without much change to the fat just under the skin. The reductions were sizable and held for a year, but reversed when treatment stopped. Important scope note: this was studied as a treatment for HIV-related fat accumulation, not as a general weight-loss drug, and general fat-loss use is off-label. ## Reported results across the pivotal trials The tesamorelin results on visceral fat are the most consistent finding in the literature. In the 26-week Phase 3 trial (n=412), visceral adipose tissue fell 15.2% on tesamorelin 2 mg/day while placebo rose 5.0%; triglycerides dropped 50 mg/dL and IGF-1 rose 81.0% [1]. Across the 52-week program, the reduction was sustained at about 18% versus baseline (P<0.001) [2]. Imaging trials sharpened the picture. The JAMA trial (n=50) measured a visceral-fat treatment effect of -42 cm2 (P=0.005) [6]. The 2024 integrase-inhibitor-era trial reported a median visceral-fat change of -25 cm2 versus +14 cm2 on placebo (P=0.001) over 12 months [9]. And the 2026 meta-analysis of five randomized trials pooled a mean reduction of 27.71 cm2 (95% CI -38.37 to -17.06; P<0.001), alongside trunk fat down 1.18 kg and lean body mass up 1.42 kg, with no serious adverse events [8]. We index these as the [reported results across the trials](/visceral-fat). ## Visceral fat, not subcutaneous fat Tesamorelin's effect is selective. Visceral adipose tissue — fat stored inside the abdominal cavity around the organs — is metabolically active and linked to insulin resistance and cardiovascular risk, and it is the tissue tesamorelin reduces [1]. Subcutaneous fat, the layer beneath the skin, generally does not change significantly, and neither does overall BMI in the trials [2]. That selectivity is what made the compound interesting for HIV-associated lipodystrophy, where the problem is specifically deep-fat accumulation, not total body weight. ## Why the effect lands on visceral fat The selectivity traces back to mechanism. Tesamorelin raises the body's own pulsatile growth hormone, and growth hormone with IGF-1 activates hormone-sensitive lipase — the enzyme that breaks stored triglycerides into free fatty acids — preferentially in visceral fat depots [1]. Visceral adipocytes are more responsive to this lipolytic (fat-splitting) drive than subcutaneous ones, which is why the deep fat moves while the layer under the skin largely does not [1][2]. That mechanism is also why the benefit is conditional. The compound accelerates breakdown of an existing depot rather than permanently reprogramming where fat is stored, so when the growth-hormone signal stops, visceral fat reaccumulates [2]. The healthy-men data anchor the upstream half of the story: two weeks of tesamorelin raised IGF-1 by 181 ug/L while leaving insulin sensitivity intact, confirming the axis is engaged before any fat endpoint is measured [4]. ## What the pooled evidence adds Single trials can be noisy; the 2026 meta-analysis pooled five randomized trials to tighten the estimate. Across them, tesamorelin reduced visceral adipose tissue by a mean 27.71 cm2 (95% CI -38.37 to -17.06), reduced trunk fat by 1.18 kg and hepatic fat fraction by 4.28%, and increased lean body mass by 1.42 kg — all statistically significant, with no serious adverse events reported [8]. The consistency across trials spanning 2007 to 2024 is itself a finding: the visceral-fat effect reproduces. It remains, in every one of those trials, an effect measured in HIV-associated lipodystrophy cohorts [8]. ## Will tesamorelin help with belly fat? In HIV-lipodystrophy trials it selectively reduced visceral abdominal fat (VAT -15.2% at 26 weeks) [1]. It was not studied as a general weight-loss agent, and general fat-loss use is off-label [5]. The studied benefit is specific to deep visceral fat in a defined patient population, not a broad slimming effect. ## How long does it take to see fat loss from tesamorelin? Pivotal HIV-lipodystrophy trials measured visceral-fat reduction at 26 weeks (VAT -15.2% vs +5.0% placebo), with the effect sustained to 52 weeks (about -18%) [1][2]. These timelines come from studied HIV populations and describe trial measurement points, not a general-use claim or a personal timeline. ## What happens when you stop taking tesamorelin? Does the fat come back? In the 52-week program, visceral fat reaccumulated after discontinuation, so the reported benefit was contingent on continued dosing [2]. The compound does not appear to durably reset deep-fat storage; when treatment stops, the deep fat returns over weeks. That reversibility is one of the central caveats in the record. --- A trial console on a dark field — the tesamorelin record read newest panel first, the FDA-approved-for-HIV-lipodystrophy scope flagged before any number and the off-label edge held lit; no clinic at this console and nothing here dosed, dispensed, or sold.